Rivaroxaban
Founded in 2017, Sigma Chemical Co., Ltd. supplies over 100 countries with high-quality chemicals. We are dedicated to safety, innovation, and global cooperation.
Product Description
Rivaroxaban (C₁₉H₁₈ClN₃O₅S, MW 435.88) is an orally bioavailable, direct Factor Xa inhibitor belonging to the oxazolidinone class of anticoagulants, characterized by a chiral (5S)-oxazolidinone core flanked by a chlorothiophene carboxamide moiety and a morpholinone-phenyl side chain that enable high-affinity, reversible binding to the S1 and S4 pockets of Factor Xa's active site. Its stereospecific synthesis—typically employing (R)-epichlorohydrin as a chiral precursor followed by Goldberg coupling and final acylation with 5-chlorothiophene-2-carbonyl chloride—yields exclusively the pharmacologically active (S)-enantiomer, which is formulated as a stable monohydrate (polymorph I) to optimize its limited aqueous solubility and achieve 80–100% oral bioavailability.
Analytical Methods
Quality control and bioanalysis primarily employ reverse-phase High-Performance Liquid Chromatography (HPLC/UPLC) with UV detection and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Chiral chromatography ensures enantiomeric purity, and X-ray powder diffraction (XRPD) confirms the correct crystalline form.
- Chemical Synthesis: Rivaroxaban is a complex, small-molecule oxazolidinone derivative. Its industrial synthesis involves a multi-step organic process, with one key reported route using a Goldberg coupling reaction as a pivotal step to construct the core structure. The synthesis starts from chiral precursors like (R)-epichlorohydrin to establish the essential (S)-configuration at the oxazolidinone ring's stereocenter, ensuring biological activity. The process includes constructing the oxazolidinone core, coupling the chlorothiophene carboxamide moiety, and introducing the morpholinone-phenyl side chain.
- Formulation: It is formulated primarily as film-coated tablets. Due to its poor aqueous solubility, formulations may include solubilizers (e.g., hydroxypropyl-β-cyclodextrin), especially for suspension preparations. The most common and stable solid form used in drug product manufacturing is the monohydrate (Form I).
Uses and Applications
Primary Medical Indications: Rivaroxaban is a direct oral anticoagulant (DOAC) used for the prevention and treatment of thromboembolic disorders.
- Venous Thromboembolism (VTE): Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent VTE. It is an alternative to low-molecular-weight heparin (e.g., dalteparin) for cancer-associated VTE.
- Atrial Fibrillation (AF): Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). Crucially, it is not recommended for stroke prevention in patients with rheumatic heart disease-associated AF, where vitamin K antagonists (VKAs) demonstrated superior efficacy in the INVICTUS trial.
- Post-Surgical Prophylaxis: Prevention of VTE following elective hip or knee replacement surgery.
- Cardiovascular Disease: Reduction of risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease (typically in combination with aspirin).
- Investigational Uses: Studies are exploring its potential in other conditions, such as improving portal hypertension complication-free survival in patients with cirrhosis (CIRROXABAN study) and for the treatment of cerebral venous thrombosis (CVT) (SECRET trial).
Properties and Characteristics
- Solubility: Practically insoluble in water and aqueous media. Soluble in organic solvents like acetone and polyethylene glycol 400.
- Chirality: It is a pure (S)-enantiomer; the stereochemistry is critical for its high affinity to factor Xa.
- Solid-State Form: Exists in multiple polymorphs; the monohydrate (Form I) is the thermodynamically stable form used commercially.
Mechanism of Action: It is a direct, selective, and reversible inhibitor of coagulation Factor Xa (FXa). It binds competitively and reversibly to the active site of FXa, inhibiting its ability to convert prothrombin to thrombin, thereby suppressing thrombus formation.
Pharmacokinetics: It has high oral bioavailability (~80-100% for the 10 mg dose). Peak plasma concentrations are reached 2-4 hours post-dose. It is metabolized primarily via CYP3A4 and is a substrate of P-glycoprotein. Approximately 66% is renally excreted (both unchanged and as metabolites).
Safety and Handling
Major Risk: The principal risk associated with rivaroxaban is bleeding, which can be serious or fatal.
Contraindications: Significant active bleeding; severe hypersensitivity reaction to rivaroxaban; patients with prosthetic heart valves or significant rheumatic heart disease (particularly mitral stenosis); pregnancy and breastfeeding (due to potential risks).
Drug Interactions:
- Strong Dual Inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, ritonavir): Significantly increase rivaroxaban exposure and bleeding risk; concomitant use is contraindicated.
- Strong CYP3A4 Inducers (e.g., rifampicin, carbamazepine): Decrease rivaroxaban exposure and reduce efficacy.
- Other Anticoagulants and Antiplatelets: Concurrent use increases bleeding risk.
Renal and Hepatic Impairment: Dosage adjustment is required (typically to 15 mg once daily) in patients with moderate to severe renal impairment (CrCl 15-50 mL/min). Use is not recommended in patients with CrCl <15 mL/min or in those with hepatic disease associated with coagulopathy.
Perioperative Management: Discontinuation is required prior to invasive or surgical procedures, considering the procedure's bleeding risk and the patient's renal function (due to rivaroxaban's ~5-9 hour half-life in healthy individuals and 11-13 hours in the elderly).
Overdose / Reversal: No specific antidote. In life-threatening bleeding, supportive measures and administration of specific reversal agents (e.g., andexanet alfa, a FXa decoy receptor) or procoagulant agents (e.g., 4-factor prothrombin complex concentrate) may be considered.
Comparative Safety: Meta-analyses of observational studies suggest that for VTE treatment, rivaroxaban may be associated with a higher risk of major bleeding compared to apixaban.